Pharmaceutical - Onyx Pharmaceuticals

Filter

Current filters:

Onyx Pharmaceuticals

Popular Filters

Bayer and Onyx report disappointing Phase III results of Nexavar in breast cancer

Bayer and Onyx report disappointing Phase III results of Nexavar in breast cancer

25-07-2014

German drug major Bayer and Onyx Pharmaceuticals, an Amgen subsidiary (Nasdaq: AMGN), have said that…

BayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearchUSA

Nexavar disappoints in Ph III liver cancer study

Nexavar disappoints in Ph III liver cancer study

11-03-2014

German pharma major Bayer and Onyx Pharmaceuticals, now a subsidiary of US biotech firm Amgen say that…

AmgenBayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearch

Drug approvals for Bayer in USA and Japan

Drug approvals for Bayer in USA and Japan

23-11-2013

There were two pieces of good news for German Pharma and chemicals major Bayer on Friday (November 22),…

AmgenAsia-PacificBayerBiotechnologyEyleaNexavarNorth AmericaOncologyOnyx PharmaceuticalsOphthalmicsPharmaceuticalRegeneronRegulation

Liver cancer market to nearly treble in size to $1.4 billion by 2019

Liver cancer market to nearly treble in size to $1.4 billion by 2019

13-11-2013

The value of the hepatocellular cancer (HCC) market is set to grow by a massive 172% and hit $1.4 billion…

BayerEuropeMarkets & MarketingNexavarNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalResearchUSA

Bayer files for EU approval of regorafenib for GIST

05-09-2013

German pharma major Bayer (BAYN: DE) said this morning (September 5) that it has submitted an application…

BayerEuropeOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibRegulationStivarga

Bayer and Onyx' Stivarga cleared in Europe

30-08-2013

In a second piece of good news within a couple of days for German drug major Bayer (BAYN: DE), the European…

BayerEuropeOncologyOnyx PharmaceuticalsPharmaceuticalRegulationStivarga

Nexavar gains FDA priority review for thyroid cancer sNDA

27-08-2013

German drug major Bayer (BAYN: DE) and partner Onyx Pharmaceuticals (Nasdaq: ONXX), which has just agreed…

BayerBiotechnologyNexavarNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulation

Onyx partners for carfilzomib managed access program in Europe

09-08-2013

US drugmaker Onyx Pharmaceuticals (Nasdaq: ONXX) is partnering with UK-based Idis Limited to initiate…

carfilzomibEuropeIdis LimitedMarkets & MarketingOncologyOnyx PharmaceuticalsPharmaceutical

Highlights from ASCO: Bayer's Nexavar; Novartis' Afinitor; and Amgen's talimogene laherparepvec

02-06-2013

The prestigious annual meeting of the American Society of Clinical Oncology (ASCO) kicked off this weekend…

AfinitorAmgenBayerBiotechnologyNexavarNovartisOncologyOnyx PharmaceuticalsPharmaceuticalResearchtalimogene laherparepvec

US and European hema-oncologists views therapies for relapsed/refractory multiple myeloma

15-05-2013

US and European hematological oncologists surveyed by health care advisory firm Decision Resources indicate…

carfilzomibEuropeKyprolisMarkets & MarketingNorth AmericaOncologyOno PharmaceuticalOnyx PharmaceuticalsPharmaceuticalpomalidomide

FDA expands use of Bayer and Onyx' Stivarga for advanced GIST

26-02-2013

The US Food and Drug Administration yesterday expanded the approved use of German drug major Bayer's…

BayerNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulationStivarga

AVEO/Astellas' kidney cancer drug tivozanib fails to beat Nexavar

14-02-2013

US biotech AVEO Oncology (Nasdaq: AVEO) and Japanese drug major Astellas Pharma (TYO: 4503) have announced…

Astellas PharmaAVEO OncologyBayerBiotechnologyNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearchtivozanib

Positive Ph III results for Bayer's Nexavar in thyroid cancer

03-01-2013

German drug major Bayer (BAYN: DE) and US partner Onyx Pharmaceuticals (Nasdaq: ONXX) this morning revealed…

BayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearch

News briefs: Bayer's Stivarga and AstraZeneca's Faslodex

30-10-2012

German drug major Bayer (BAYN: DE) and US partner Onyx Pharmaceuticals (Nasdaq: ONXX) said yesterday…

AstraZenecaBayerFaslodexNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulationResearchStivarga

Bayer's Stivarga races to FDA approval on the heels of Zaltrap

07-10-2012

The earlier than expected US Food and Drug Administration approval of German drug major Bayer's (BAYN:…

BayerBiotechnologyMarkets & MarketingNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibRegulationSanofiStivargaZaltrap

Bayer files NDA for regorafenib for the treatment of GIST

31-08-2012

The US subsidiary of Germany's Bayer (BAYB: DE) has submitted a New Drug Application to the US Food and…

BayerBiotechnologyNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibRegulation

Adding Tarceva to Nexavar no better than Nexavar alone for liver cancer

23-07-2012

A Phase III trial evaluating the efficacy and safety of the addition of Roche's Tarceva (erlotinib) tablets…

Astellas PharmaBayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearchTarceva

News briefs: US priority review for regorafenib; Ph IIb blisibimod data

29-06-2012

Bayer HealthCare, a US unit of Germany's Bayer (BAYN: DE) and partner Onyx Pharmaceuticals (Nasdaq: ONXX)…

Anthera PharmaceuticalsBayerBiotechnologyblisibimodOncologyOnyx PharmaceuticalsPharmaceuticalRare diseasesregorafenibRegulationResearch

Batch of mixed opinions from FDA advisory panels

21-06-2012

Advisory panels of the US Food and Drug Administration meeting yesterday came back with a mixture of…

carfilzomibKyprolisMerck & CoNorth AmericaOncologyOnyx PharmaceuticalsPfizerPharmaceuticalPneumovaxPrevnarRegulationSanofisemuloparinVaccines

Bayer and Onyx' Nexavar fails in Ph III lung cancer study

23-05-2012

There was disappointment for German drug major Bayer (BAYB: DE) and partner Onyx Pharmaceuticals (Nasdaq:…

BayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearch

Senior appointments as Sanofi and Onyx

05-03-2012

French drug major Sanofi (Euronext: SAN) has named former Bayer executive Jean-Luc Lowinski as senior…

ManagementOnyx PharmaceuticalsPharmaceuticalSanofi

Back to top